September 19, 2019 — The FDA issued a warning about a rare but life-threatening risk of lung inflammation from certain breast cancer drugs.
The breast cancer drugs Ibrance® (palbociclib), Kisqali® (ribociclib), and Verzenio® (abemaciclib) are linked to a potentially deadly side effect called Interstitial Lung Disease (ILD) or pneumonitis.
Patients who are taking these cancer drugs should tell their healthcare professional immediately if they develop symptoms of lung inflammation, such as new or worsening breathing problems.
The symptoms of lung inflammation include trouble breathing, discomfort or pain with breathing, and shortness of breathe while at rest or during low activity.
The FDA is asking drug-manufacturers to update the warning labels on their breast cancer drugs to include this new risk information.
The risk is low, but several deaths and serious cases of lung inflammation occurred during clinical trials for Ibrance, Kisqali, and Verzenio. Some patients died despite having no risk-factors for lung disease. Across clinical trials for all three drugs, 1-3% of patients developed lung inflammation or pneumonitis, according to the FDA.
Do I have a Breast Cancer Drug Injury Lawsuit?
The Schmidt Firm, PLLC is currently accepting lung disease induced injury cases in all 50 states. If you or somebody you know has been diagnosed with lung inflammation or pneumonitis from Ibrance, Kisqali or Verzenio, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.